Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original Article

Clinical features of neonates born to mothers with coronavirus disease-2019: A systematic review of 105 neonates

Hsin Chi a,b,1, Nan-Chang Chiu a,b,1, Yu-Lin Tai c, Hung-Yang Chang a,b, Chao-Hsu Lin c,d, Yi-Hsiang Sung c, Cheng-Yin Tseng e, Lawrence Yu-Min Liu b,e, Chien-Yu Lin b,c,*

a Department of Pediatrics, MacKay Memorial Hospital, Taipei 104, Taiwan
b Department of Medicine, MacKay Medical College, New Taipei 252, Taiwan
c Department of Pediatrics, Hsinchu Mackay Memorial Hospital, Hsinchu 300, Taiwan
d Department of Biological Science and Technology, National Chiao-Tung University, Hsinchu 300, Taiwan
e Department of Internal Medicine and Evidence-Based Medicine, Hsinchu Mackay Memorial Hospital, Hsinchu 300, Taiwan

Received 29 May 2020; received in revised form 17 July 2020; accepted 30 July 2020
Available online 14 August 2020

KEYWORDS
Novel coronavirus; COVID-19; SARS-CoV-2; Vertical transmission; Intrauterine infection; Neonate

Abstract  Background: Despite the increasingly recognized impact of novel coronavirus disease (COVID-19), caused by severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), on many aspects of health in adults and children, its effects on neonates born to infected mothers remain unclear. We conducted this study to investigate the outcomes of neonates born to mothers with COVID-19.

Methods: We searched the medical databases from inception to March 31, 2020 to perform a systematic review of outcomes in neonates born to mothers with COVID-19. Data were pooled using a random effects regression model. Primary and secondary outcomes were neonatal clinical outcomes and infectious status, respectively.

Results: Fourteen studies involving 105 neonates fulfilling the study criteria were identified. The rates of preterm neonates and those small for gestational age (SGA) were 25 (23.8%) and 10 (11.2%), respectively. Among 91 neonates who were tested, 8 (8.8%) were positive for nucleic acids or antibodies for SARS-CoV-2. Additionally, 28 (26.7%) of the neonates were symptomatic and two test-negative neonates died, including one stillbirth. Between test-
positive and test-negative groups, the rates of SGA, preterm delivery, duration between maternal symptom onset and delivery, and perinatal complication were not significantly different; but the rate of symptomatic after birth reached significant difference (62.5% vs 20.5%, \( p = 0.008 \)).

**Conclusions:** Most neonates born to infected mothers had favorable outcomes. Although direct evidences of intrauterine infection were scarce, the risk of intrauterine infection should be considered based on a positive test in 8.8% of the neonates. Symptomatic neonates born to infected mothers should receive tests for SARS-CoV-2 to initiate appropriate treatment and quarantine. Further studies are warranted to assess the outcomes of COVID-19 in neonates.

**Methods**

**Study design and study selection**

Our study was approved by the Institutional Review Board of the MacKay Memorial Hospital, Taipei, Taiwan (approval number: 20MMHS140e). We performed the present systematic review and meta-analysis in accordance with the PRISMA guidelines (Fig. 1, Supplementary Table 1).11

In the present systematic review, we used comprehensive keywords with Boolean operators and MeSH terms to perform electronic search of the following medical databases from inception to March 31, 2020, supplemented with hand searching: PubMed/Medline, EMBASE, Cumulative Index to Nursing and Allied Health Literature, National Digital Library of Theses and Dissertations in Taiwan database, Art Image Indexing Service on the Internet Database (Chinese database), and the Cochrane database. The search was performed independently by two authors, and disagreements were resolved through discussion with the third author. Briefly, the electronic search included the keywords “COVID-19,” “severe acute respiratory syndrome coronavirus 2,” “2019-nCoV,” “SARS-CoV-2,” and “Wuhan.” No constraints were placed on language, year of publication, and participant characteristics to ensure a comprehensive search and identify the maximum number of potential articles. Authors of specific articles were contacted to obtain additional information if necessary.

**Data extraction, quality assessment, and data synthesis and analysis**

Studies investigating “pregnancy,” “pregnant,” “mother,” “neonates,” “infant,” or “children” were analyzed. Exclusion criteria were duplicate publications, irrelevant articles, studies where the status of children was not clearly defined, studies that did not evaluate clinical outcomes, and review articles. Primary and secondary outcomes were neonatal clinical outcomes and infectious status, respectively.

Furthermore, two authors independently appraised the selected articles and extracted the following data: name of the first author, study country, participant population, gestational age, perinatal complications, mode of delivery, neonatal outcomes, site of sampling, and COVID-19 test results. Preterm delivery was defined as gestational age less than 37 complete weeks. Poor outcomes of mothers or neonates were defined as requiring intensive care, mechanical ventilator or inotropic agents use, multiple organ failure, extracorporeal membrane oxygenation use, or mortality. In case of a disagreement between two authors, consensus was reached through discussion with the third author. The quality assessment was conducted independently by two authors based on the domains of selection, ascertainment, causality and reporting.12

---

**Introduction**

Coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) is an emerging disease with a massive disease burden.1-4 The main manifestations of COVID-19 include fever and respiratory symptoms; however, the clinical presentations are protean. Infected patients might have gastrointestinal symptoms, anosmia, hyposmia, or dysgeusia5,6 or may otherwise be asymptomatic; thus, controlling the disease spread is difficult. Approximately 20% of infected patients have severe disease, and the approximate case-fatality rate is 5%–6%.6-8 Older individuals and those with underlying diseases are at a higher risk for poor outcomes. Conversely, the effect of COVID-19 on pregnancy remains largely unclear although pregnant women are susceptible to various viral infections such as influenza virus and SARS.

In a retrospective study of 38 SARS-CoV-2-infected mothers, Schwartz et al. reported that the clinical manifestations of infected mothers were similar to those who were not pregnant.9 No additional pregnancy risk was found in patients with COVID-19, and there was no evidence of intrauterine infection.7 However, in a study of 33 neonates, Zeng et al. reported that three neonates had a positive nucleic acid test for SARS-CoV-2.10 The complete features of SARS-CoV-2-infected pregnant women and neonates born to infected mothers remain largely unclear. Therefore, we conducted a systematic review to investigate the clinical features of neonates born to mothers with COVID-19.
Statistical analyses

If continuous outcomes were assessed, data were analyzed using odds ratios with 95% confidence intervals. For categorized variables, comparison was performed using Student’s t test and the chi-square test. If meta-analysis was performed, we used a random-effects regression model assuming that the true effect size was not the same. Heterogeneity was further quantified using the Cochran Q test and $I^2$ statistics. A p value less than 0.05 was regarded as statistically significant. Review Manager v5.3.5 (Cochrane Community, London, UK) and SPSS version 23.0 (SPSS, Chicago, IL, USA) were used for statistical analyses.

Results

Description of studies and quality assessment

The search process is illustrated in Fig. 1. As of March 31, 2020, 2060 articles were identified by the medical database search. The titles and abstracts of all articles were screened and 71 full-text articles were carefully reviewed. Finally, 14 studies fulfilling the inclusion and exclusion criteria were included in the final systematic review.10,15-27

Clinical features and neonatal outcomes

The clinical features of the included studies are summarized in Table 1. Most studies had good quality. All studies were conducted in China, and 107 mothers with confirmed COVID-19 were identified. Three mothers had not delivered at the publication time of the original study, and there were a total of 105 neonates including one set of twins. The mothers were aged between 22 and 40 years, and 43 mothers developed perinatal complications including pre-eclampsia, placenta previa, placenta abruptio, fetal distress, premature rupture of membranes, and uterine scarring. Most mothers had uneventful recovery except for one mother who developed acute respiratory distress syndrome and multiple organ failure requiring extra-corporeal membrane oxygen.20 Majority of the mothers (87.6%) underwent cesarean section (CS), and 25 (23.8%) neonates were delivered prematurely. 76 (83.5%) mothers had fever or respiratory symptoms. Among mothers with clear records of onsets, 8 (22.2%) mothers developed symptoms after delivery. After birth, 28 (26.7%) neonates exhibited
| Study ref | Maternal population (N) | Neonatal population (N) | Maternal age (years) | Preterm delivery (N) | Perinatal complications | CS (N) | SGA (N) | Maternal symptoms? | Maternal symptoms onset to delivery (days) | Maternal symptoms onset to delivery (test-positive) | Neonatal symptoms | Intensive care | Neonatal poor outcomes | Maternal poor outcomes |
|-----------|-------------------------|-------------------------|----------------------|----------------------|-------------------------|--------|---------|-------------------|---------------------------------------------|------------------------------------------------|-----------------|--------------|---------------------|---------------------|
| Chen et al.15 | 9                       | 9                        | 26–40                | 4                    | 5                       | 9      | 2       | 9                 | 1, 1, 2, 2, 3, 4, 6, 7                     | NR                                 | 0               | 0            | 0                   | 0                   |
| Chen et al.16 | 3                       | 3                        | 23–34                | 1                    | 3                       | 3      | 1       | 3                 | 2 after delivery                          | NR                                 | 1               | 0            | 0                   | 0                   |
| Chen et al.27 | 5                       | 5                        | 25–31                | 0                    | 3                       | 2      | 0       | 5                 | −1, −1, −1, 1, 10                           | NR                                 | 0               | 0            | 0                   | 0                   |
| Dong et al.17 | 1                       | 1                        | 29                   | 0                    | 0                       | 1      | 0       | 1                 | 25                                           | 25                                | 0               | 0            | 0                   | 0                   |
| Fan et al.18  | 2                       | 2                        | 29, 34               | 1                    | 0                       | 2      | 0       | 2                 | 7, 11                                       | 2                                      | 0               | 0            | 0                   | 0                   |
| Li et al.19   | 1                       | 1                        | 30                   | 1                    | 1                       | 1      | 0       | 1                 | 4                                           | NR                                    | 0               | 0            | 0                   | 0                   |
| Liu et al.20  | 13                      | 10                       | 22–36                | 6                    | 5                       | 10     | NR      | 9                 | NR                                          | NR                                    | 0               | 0            | 1                   | 1                   |
| Wang et al.21 | 1                       | 1                        | 34                   | 0                    | 0                       | 1      | 0       | 1                 | 0.5                                          | 0.5                                  | 1 (vomiting) | 0            | 0                   | 0                   |
| Wang et al.22 | 1                       | 1                        | 28                   | 1                    | 1                       | 1      | 1       | 1                 | 6                                           | 0                                    | 0               | 0            | 0                   | 0                   |
| Yu et al.23   | 7                       | 7                        | 29–34                | 0                    | 3                       | 7      | 0       | 7                 | NR                                          | NR                                    | 1               | 0            | 0                   | 0                   |
| Zeng et al.24 | 6                       | 6                        | NR                   | 0                    | NR                      | 6      | NR      | 6                 | NR                                          | NR                                    | 0               | 0            | 0                   | 0                   |
| Zeng et al.25 | 33                      | 33                       | NR                   | 4                    | 3                       | 26     | 3       | 22                | 1, 2, 4                                     | 1, 2, 4                             | 4               | 1            | 0                   | 0                   |
| Zhang et al.26 | 16                      | 16                       | 24–34                | 1                    | 12                      | 16     | 1       | NR                | 6                                            | 0                                    | 0               | 0            | 0                   | 0                   |
| Zhu et al.27  | 9                       | 10                       | 25–35                | 6                    | 7                       | 7      | 2       | 9                 | −3, −2, −1, 0, 0, 1, 3, 3, 4, 6             | 0                                    | 1               | 1            | 0                   | 0                   |

| Study ref | Neonatal population (N) | Neonates tested (N) | Positive Ab (N) | Positive PCR (N) | Sites of PCR sampling | Suggestive vertical transmission? |
|-----------|-------------------------|---------------------|----------------|-----------------|-----------------------|----------------------------------|
| Chen et al.15 | 9                       | 6                   | 0              | 0               | Amniotic fluid, cord blood, throat swab, breastmilk | No                              |
| Chen et al.16 | 3                       | 3                   | 0              | 0               | Pharyngeal swab, placenta | No                              |
| Chen et al.27 | 5                       | 5                   | 0              | 0               | Pharyngeal swab        | No                              |
| Dong et al.17 | 1                       | 1                   | 1              | 0               | Negative PCR: swab; positive IgG/IgM | Yes                             |
| Fan et al.18  | 2                       | 2                   | 0              | 0               | Newborn’s nasopharyngeal swab, maternal serum, placenta, cord blood, amniotic fluid, vaginal swabs, and breast milk | No                              |
| Li et al.19   | 1                       | 1                   | 0              | 0               | Amniotic fluid, cord blood, breastmilk, pharyngeal swab, blood, feces, and urine samples | No                              |
| Liu et al.20  | 10                      | 10                  | 0              | 0               | No clinical or serologic evidence suggestive of vertical transmission of SARS-CoV-2 | No                              |
| Wang et al.21 | 1                       | 1                   | 1              | Pharyngeal swab at 36 h; negative cord blood, placenta, breastmilk | Possible                          |
| Wang et al.22 | 1                       | 1                   | 0              | Amniotic fluid, placenta, cord blood, gastric juice, throat swab, and stool sample | No                              |
symptoms including fever, tachypnea, shortness of breath, and vomiting. There was one stillbirth, and one neonate died following gastric bleeding and multiple organ failure.20,26

Risk of vertical transmission and tests for SARS-CoV-2

Considering the risk of vertical transmission, 91 (86.7%) neonates were tested for SARS-CoV-2 by a nucleic acid or antibody test. Five neonates were positive by the nucleic acid test, and three neonates were positive for SARS-CoV-2 antibodies. The authors of three enrolled studies thought the risk of vertical transmission existed10,17,24; two studies found positive nucleic acid at 36 h that postnatal infections were unable to be completely excluded.21,23 No evidence of vertical transmission was found in the rest of the studies.

Of the 105 neonates, 91 neonates were tested for SARS-CoV-2 and 8 (8.8%) neonates had a positive nucleic acid or antibody test result. Further comparison of the clinical manifestations between the test-positive and test-negative neonates (Table 2) revealed that the rates of neonates who were small for gestational age (SGA) and those exhibiting symptoms after birth were higher among those with a positive test. However, the rates of preterm delivery and perinatal complications were lower among the test-positive neonates. Between both groups, the rates of SGA, preterm delivery, duration between maternal symptom onset and delivery, and perinatal complication were not significantly different but the rate of symptomatic after birth reached significant difference.

Discussion

The present systematic review evaluating the currently unknown impact of SARS-CoV-2 on neonates born to mothers with COVID-19 revealed that most neonates had a favorable outcome. Importantly, 8.8% of the tested neonates were positive for SARS-CoV-2, indicating that the risk of vertical transmission should be considered. Compared with the test-negative neonates, the rates of SGA, preterm delivery, duration between maternal symptom onset and delivery, and perinatal complication were not significantly different but the rate of symptomatic after birth reached significant difference between both groups. Therefore, further studies are warranted to elucidate the impact of COVID-19 on pregnancy and neonates.

Pregnant women have unique physiologic changes and are susceptible to several viral infections such as influenza and SARS.28,29 The present systemic review to address the concerns regarding COVID-19 infection in pregnant women revealed that the clinical manifestations of COVID-19 were similar between mothers and non-pregnant individuals. All but one mother had relatively favorable outcomes.20 Pregnant women had similar clinical presentations and risk of severe complications compared with non-pregnant individuals of the same age group.5,6 The low risk of severe COVID-19 in pregnant women might be due to the relatively younger patient age and the absence of underlying diseases. However, the expression of angiotensin-converting enzyme 2, a predicted SARS-CoV-2 receptor,
was reported to be increased during pregnancy. Moreover, the increased expression of angiotensin-converting enzyme 2 was observed in adolescents with preterm delivery in previous report and preterm neonates might have higher risk of COVID-19. We found a lower rate of preterm delivery in test-positive neonates but the difference was not statistically significant. Despite the increasing number of studies investigating COVID-19, the exact underlying pathophysiology has not been elucidated and further studies are warranted to clarify the relationship between SARS-CoV-2 and pregnancy.

When taking care of expectant mothers with COVID-19, the risk of intrauterine infection and vertical transmission was an important concern. Eight of the studies included in the systematic review found no evidence of vertical transmission and could not detect the virus in amniotic fluid, cord blood, breast milk, serum, feces, placenta, nasopharyngeal, rectal, or vaginal swabs. However, two of the included studies found elevated levels of SARS-CoV-2 immunoglobulin (Ig) G and IgM antibodies in three neonates; however, the nucleic acid tests were negative, and the evidence was not convincing. IgM is a larger molecule that does not usually transfer from mother to fetus and does not appear until 3–7 days after infection. The presence of neonatal SARS-CoV-2 IgM raises the possibility of intrauterine infection. However, there are several kinds of antibody tests against SARS-CoV-2 and the concerns regarding the sensitivity and specificity of present available antibody tests exist. Maternal IgM may reach fetal circulation in case of placental inflammation. These studies with positive neonatal IgM provide evidence for additional investigation. Furthermore, SARS-CoV-2 nucleic acids were detected in five neonates. However, the strength of this direct evidence might be challenged by the sampling time of 24–36 h after birth thus postnatal infection cannot be completely excluded. Naturally the fetal circulation bypass lungs and virus might be not lodged in the airway mucosa before delivery. However, the authors claimed strict infectious control measurements had been implemented for neonates after birth thus the risk of postnatal infection was minimal. Further nucleic acid tests performed right after delivery were valuable to elucidate the origin of infection and the route of infection remained largely unclear based on present evidences. Additionally, our analyses determined that the rate of neonates exhibiting symptoms after birth was higher among the test-positive neonates than in the test-negative neonates (Table 2, 62.5% vs 20.5%, p = 0.008), which might reflect the possible role of congenital infections. We also observed a longer duration between maternal symptom onset and delivery in test-positive neonates (Table 2, 6.5 vs 2.75 days, p = 0.469). Patients with COVID-19 might have deteriorated clinical conditions in approximate 7 days after symptom onset. The coincidence of 6.5 and 7 days caught our attention but we failed to identify the significant predictive factors of neonatal infection, including maternal fever, respiratory symptoms, laboratory findings, or perinatal conditions. Despite the controversies, the present systematic review demonstrated that 8.8% of the neonates had a positive nucleic acid or antibody test and that the risk of vertical transmission should be considered. Further studies utilizing both nucleic acid and antibody tests will be valuable to provide further evidence for correlations between clinical symptoms and viral tests. Further direct evidences from amniotic fluid, placenta, umbilical cord and neonates are valuable to draw a definite conclusion.

We found that 26.7% of the neonates born to mothers with COVID-19 were symptomatic after birth and that most of the symptoms were mild. Additionally, 25 neonates were delivered preterm and cesarean section was performed in 87.6% of the cases. Reasons of CS included uncertainty about the risk of intrapartum mother-to-child transmission by vaginal delivery, severe pre-eclampsia, fetal distress, and previous CS. Neonates with preterm delivery and CS are at a higher risk of transient tachypnea of newborn, and determining whether the observed symptoms were due to SARS-CoV-2 infection is difficult. Although the rate of symptomatic neonates was higher among those with a positive test, the casual relationship could not be clarified. Moreover, cesarean section was performed in the majority of mothers to control perinatal complications and infections, and 13 neonates who were delivered via normal spontaneous labor were negative for SARS-CoV-2. Further studies are warranted to investigate the need for cesarean section to reduce the rate of perinatal infections including SARS-CoV-2.

The present study has several limitations that should be acknowledged. First, the results of laboratory tests, inflammatory markers, and imaging studies were not available in some studies. Although most neonates had favorable outcomes, details of infectious survey are necessary for a better evaluation of the COVID-19 infection status and to obtain a more complete picture of neonatal COVID-19. Second, the situation of COVID-19 pandemic changed

| Clinical variables | Preterm delivery | Perinatal complications | Maternal symptom onset to delivery (days) | CS | SGA | Symptomatic neonates | Positive PCR or Ab |
|-------------------|-----------------|-------------------------|---------------------------------------|----|-----|----------------------|-------------------|
| All neonates (105) | 25 (23.8)       | 43 (42.6)               | 3.32                                  | 92 (87.6) | 10 (11.2) | 28 (26.7) | 8 (8.8) |
| Test-negative (83) | 22 (26.5)       | 34/79 (43)             | 2.75 ± 3.5                             | 73 (88) | 7/69 (10.1) | 17 (20.5) |
| Test-positive (8)  | 1 (12.5)        | 1/6 (16.7)             | 6.5 ± 10.4                             | 8 (100) | 1/6 (16.7) | 5 (62.5) | 0.008 |

*Presented as numbers (%).
Ab, antibody; CS, cesarean section; PCR, polymerase chain reaction; SGA, small for gestational age.
rapidly and bigger cohorts will be helpful for a better assessment of COVID-19’s impact on neonates, including the risk of vertical transmission and breastfeeding, differences based on gestational age, and impact of the duration between exposure and delivery. Third, although the quality of most studies were good, case series didn’t provide high-ranked evidences. Randomized controlled studies were appreciated but it’s ethically impossible to conduct a randomized control study. Finally, all enrolled studies were conducted in China, the neonatal outcomes may differ across races, geographic regions, healthcare resources, and time. Further studies are necessary to address these important questions.

Conclusions

In conclusion, the present systematic review of 14 studies comprising 105 neonates born to mothers with COVID-19 revealed that the outcome was favorable in most neonates. However, 8.8% neonates had a positive nucleic acid or antibody test. Although direct evidences of vertical transmission remained scarce, the risk of vertical transmission should be considered. Neonates with a positive test had a higher rate of symptoms after birth, a finding warranting further investigation. Symptomatic neonates born to mothers with COVID-19 should receive testing for SARS-CoV-2 to initiate appropriate quarantine and treatment.

Funding

We received no funding and we thanked everyone’s efforts to combat COVID-19.

Ethical approval

This study was approved by the ethical committee of MacKay Memorial Hospital (No.: 20MMHIS140e).

Declaration of competing interest

All authors had no competing interests to disclose.

References

1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020;55:105924.
2. Lee PI, Hsueh PR. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Infect 2020;53:365–7.
3. Lee PI, Hu TL, Chen CY, Huang HC, Hsueh PR. Are children less susceptible to COVID-19? J Microbiol Infect 2020;53:371–2.
4. Chang CM, Tan TW, Ho TC, Chen CC, Su TH, Lin CY. COVID-19: Taiwan’s epidemiological characteristics and public and hospital responses. PeerJ 2020;8:e9360.
5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20.
6. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. J Am Med Assoc 2020. https://doi.org/10.1001/jama.2020.2648 [published Online First: 25/02/20].
7. WHO. Coronavirus disease (COVID-19) outbreak situation 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. [Accessed 1 April 2020].
8. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 2020;92:577–83.
9. Schwartz DA. An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes. Arch Pathol Lab Med 2020. https://doi.org/10.5858/arpa.2020-0901-SA [published Online First: 18/03/20].
10. Zeng L, Xia S, Yuan W, Yan K, Xiao F, Shao J, et al. Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China. JAMA Pediatr 2020;174:722–5.
11. Shamseer L, Moher D, Clarke M, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.
12. Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med 2018;23:60–3.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Contr Clin Trials 1986;7:177–88.
14. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58.
15. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020;395:809–15.
16. Chen S, Huang B, Luo DJ, Li X, Yang F, Zhao Y, et al. Pregnancy with new coronavirus infection: clinical characteristics and placental pathological analysis of three cases. Zhonghua Bing Li Xue Za Zhi 2020;49:418–23.
17. Dong L, Tian J, He S, Zhu C, Wang J, Liu C, et al. Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn. J Am Med Assoc 2020;323:1846–8.
18. Fan C, Lei D, Fang C, Li C, Wang M, Liu Y, et al. Perinatal transmission of COVID-19 associated SARS-CoV-2: should we worry? Clin Infect Dis 2020;ciaa226. https://doi.org/10.1093/cid/ciaa226 [published Online First: 18/03/20].
19. Li Y, Zhao R, Zheng S, Chen X, Wang J, Sheng X, et al. Lack of vertical transmission of severe acute respiratory syndrome coronavirus 2, China. Emerg Infect Dis 2020;26:1335–6.
20. Liu Y, Chen H, Tang K, Guo Y. Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy. J Infect 2020. https://doi.org/10.1016/j.jinf.2020.02.028 [published Online First: 08/03/20].
21. Wang S, Guo L, Chen L, Liu W, Cao Y, Zhang J, et al. A case report of neonatal COVID-19 infection in China. Clin Infect Dis 2020. https://doi.org/10.1093/cid/ciaa225 [published Online First: 13/03/20].
22. Wang X, Zhou Z, Zhang J, Zhu F, Tan Y, Shen X. A case of 2019 novel coronavirus in a pregnant woman with preterm delivery. Clin Infect Dis 2020. https://doi.org/10.1093/cid/ciaa200 [published Online First: 03/03/20].
23. Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective,
single-centre, descriptive study. *Lancet Infect Dis* 2020;20:559–64.
24. Zeng H, Xu C, Fan J, Tang Y, Deng Q, Zhang W, et al. Antibodies in infants born to mothers with COVID-19 pneumonia. *J Am Med Assoc* 2020;323:1848–9.
25. Zhang L, Jiang Y, Wei M, Cheng BH, Zhou XC, Li J, et al. Analysis of the pregnancy outcomes in pregnant women with COVID-19 in Hubei Province. *Zhonghua Fu Chan Ke Za Zhi* 2020;55:166–71.
26. Zhu H, Wang L, Fang C, Peng S, Zhang L, Chang G, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. *Transl Pediatr* 2020;9:51–60.
27. Chen S, Liao E, Cao D, Gao Y, Sun G, Shao Y. Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia. *J Med Virol* 2020. https://doi.org/10.1002/jmv.25789 [published Online First: 30/03/20].
28. Wong SF, Chow KM, Leung TN, Ng WF, Ng TK, Shek CC, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. *Am J Obstet Gynecol* 2004;191:292–7.
29. Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL, Biggerstaff MS, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. *Lancet* 2009;374:451–8.
30. Levy A, Yagil Y, Bursztyn M, Barkalifa R, Scharf S, Yagil C. ACE2 expression and activity are enhanced during pregnancy. *Am J Physiol Regul Integr Comp Physiol* 2008;295:R1953–61.
31. Devaux CA, Rolain J-M, Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. *J Microbiol Immunol Infect* 2020;53:425–35.
32. South AM, Nixon PA, Chappell MC, Diz DI, Russell GB, Jensen ET, et al. Association between preterm birth and the renin-angiotensin system in adolescence: influence of sex and obesity. *J Hypertens* 2018;36:2092–101.
33. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497–506.

**Appendix A. Supplementary data**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jmii.2020.07.024.